loading
Precedente Chiudi:
$0.1172
Aprire:
$0.0268
Volume 24 ore:
149.41K
Relative Volume:
66.00
Capitalizzazione di mercato:
$N/A
Reddito:
$9.94M
Utile/perdita netta:
$-144.49M
Rapporto P/E:
-0.00594
EPS:
-5.05
Flusso di cassa netto:
$-103.90M
1 W Prestazione:
-73.55%
1M Prestazione:
-79.82%
6M Prestazione:
-98.42%
1 anno Prestazione:
-99.50%
Intervallo 1D:
Value
$0.0257
$0.03
Intervallo di 1 settimana:
Value
$0.0257
$0.03
Portata 52W:
Value
$0.0257
$0.03

Syros Pharmaceuticals Inc Stock (SYRS) Company Profile

Name
Nome
Syros Pharmaceuticals Inc
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
SYRS's Discussions on Twitter

Confronta SYRS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
SYRS
Syros Pharmaceuticals Inc
0.03 0 9.94M -144.49M -103.90M -5.05
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2020-11-04 Aggiornamento H.C. Wainwright Neutral → Buy
2020-09-22 Iniziato Alliance Global Partners Buy
2020-01-17 Downgrade Wedbush Outperform → Neutral
2019-03-08 Ripresa JMP Securities Mkt Outperform
2019-02-14 Ripresa Oppenheimer Outperform
2018-11-05 Aggiornamento ROTH Capital Neutral → Buy
2018-03-13 Reiterato Wedbush Outperform
2017-10-31 Ripresa Piper Jaffray Overweight
2017-10-23 Iniziato ROTH Capital Neutral
2017-08-10 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Mostra tutto

Syros Pharmaceuticals Inc Borsa (SYRS) Ultime notizie

pulisher
03:52 AM

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives Consensus Rating of “Hold” from Analysts - Defense World

03:52 AM
pulisher
May 30, 2025

SYROS PHARMACEUTICALS Earnings Preview: Recent $SYRS Insider Trading, Hedge Fund Activity, and More - Nasdaq

May 30, 2025
pulisher
May 16, 2025

Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com - Defense World

May 16, 2025
pulisher
May 12, 2025

Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.

May 12, 2025
pulisher
May 08, 2025

Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated by Analysts at StockNews.com - Defense World

May 08, 2025
pulisher
May 07, 2025

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives Consensus Recommendation of “Hold” from Analysts - Defense World

May 07, 2025
pulisher
May 02, 2025

StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World

May 02, 2025
pulisher
May 01, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 01, 2025
pulisher
Apr 22, 2025

StockNews.com Initiates Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World

Apr 22, 2025
pulisher
Apr 15, 2025

Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals - MSN

Apr 15, 2025
pulisher
Apr 15, 2025

Rege Nephro Acquires Assets from Syros Pharmaceuticals (SYRS) - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS) | SYRS Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Major Kidney Disease Drug Acquisition: Rege Nephro Takes Over Syros' Phase 2 Asset - Stock Titan

Apr 15, 2025
pulisher
Apr 15, 2025

Rege Nephro Acquires Tamibarotene-Related Assets from Syros Phar - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials - digitalmore.co

Apr 15, 2025
pulisher
Apr 14, 2025

Syros Pharma pulls out of deal with RaQualia - The Pharma Letter

Apr 14, 2025
pulisher
Apr 14, 2025

Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated at StockNews.com - Defense World

Apr 14, 2025
pulisher
Apr 12, 2025

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Given Average Recommendation of “Hold” by Brokerages - Defense World

Apr 12, 2025
pulisher
Mar 27, 2025

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Short Interest Up 345.9% in March - Defense World

Mar 27, 2025
pulisher
Mar 21, 2025

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives $3.33 Average PT from Brokerages - Defense World

Mar 21, 2025
pulisher
Mar 19, 2025

Syros Pharmaceuticals (SYRS) to Release Earnings on Wednesday - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

Dow Dips Over 200 Points; US Industrial Production Increases More than Expected - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga India

Mar 18, 2025
pulisher
Mar 17, 2025

Analyze Syros Pharmaceuticals Inc (NASDAQ: SYRS) Before Investing. - stocksregister.com

Mar 17, 2025
pulisher
Mar 14, 2025

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Mar 14, 2025
pulisher
Mar 13, 2025

Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights

Mar 13, 2025
pulisher
Mar 12, 2025

12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga

Mar 12, 2025
pulisher
Mar 12, 2025

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Mar 12, 2025
pulisher
Mar 12, 2025

Pre-market Movers: HCTI, HEPA, ZYXI, SYRS ... - RTTNews

Mar 12, 2025
pulisher
Mar 11, 2025

US Stocks Mixed; Kohl's Shares Plunge After Q4 Results - Benzinga

Mar 11, 2025
pulisher
Mar 10, 2025

Aptevo Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:APVO - Benzinga

Mar 10, 2025
pulisher
Mar 07, 2025

Syros Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 04, 2025

Syros Pharmaceuticals settles debt with Oxford Finance By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

Syros Pharmaceuticals settles debt with Oxford Finance - Investing.com India

Mar 04, 2025
pulisher
Mar 03, 2025

Why US Stock Futures Are Rising TodayInvesco QQQ Trust, Series 1 (NASDAQ:QQQ), SPDR S&P 500 (ARCA:SPY) - Benzinga

Mar 03, 2025
pulisher
Mar 01, 2025

Syros Pharmaceuticals, Inc. Announces Cessation of Gerald Quirk as Chief Executive Officer, Effective March 01, 2025 - Marketscreener.com

Mar 01, 2025
pulisher
Mar 01, 2025

Syros Pharmaceuticals, Inc. Announces Management Changes -February 28, 2025 at 04:15 pm EST - Marketscreener.com

Mar 01, 2025
pulisher
Feb 28, 2025

Stocks to Watch: Toro, Syros Pharmaceuticals - MarketWatch

Feb 28, 2025
pulisher
Feb 28, 2025

Syros to delist from Nasdaq, deregister from SEC - MSN

Feb 28, 2025
pulisher
Feb 28, 2025

Syros Pharmaceuticals Delists from Nasdaq Amid Restructuring - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Syros Pharmaceuticals to Delist from Nasdaq, Deregister Common Shares -February 28, 2025 at 04:41 pm EST - Marketscreener.com

Feb 28, 2025
pulisher
Feb 28, 2025

Syros Pharmaceuticals voluntarily delists from Nasdaq, deregisters common stock - TipRanks

Feb 28, 2025

Syros Pharmaceuticals Inc Azioni (SYRS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Capitalizzazione:     |  Volume (24 ore):